Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Blood safety (8)
- (-) Weight loss products (1)
- Alert/Advisory (1067)
- Medicine safety (493)
- Medical devices safety (343)
- Safety (61)
- Regulatory compliance (23)
- Import and export (18)
- Listed medicines (16)
- Prescription medicines (16)
- Over the counter (OTC) medicines (14)
- Therapeutic goods regulation (14)
- Complementary medicines (12)
- Australian Register of Therapeutic Goods (ARTG) (11)
- Shortages (11)
- Non-prescription medicines (7)
- Advertising (4)
- Labelling and packaging (3)
- Sunscreens (3)
- Breast implant hub (2)
- Legislation (2)
- Assessed listed medicines (1)
- Compliance and enforcement hub (1)
- Metal-on-metal hip replacement implants hub (1)
- Registered complementary medicines (1)
Search
9 result(s) found, displaying 1 to 9
-
Safety alertsFurther examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
-
Safety alertsOn 21 March 2012, the TGA agreed that the release procedure involving TGA's batch-by-batch review of CSL's ethylene glycol test results need not apply to batches of albumin solution manufactured after 25 January 2012.
-
Safety alertsQuarantine of some CSL Biotherapies batches of human albumin product (ALBUMEX) pending further analysis
-
Safety alertsCSL Biotherapies notified the TGA on 7 March 2012 that some batches of human albumin solutions manufactured prior to 25 January 2012 have been contaminated with ethylene glycol as a consequence of an equipment failure.
-
Safety alertsThe Therapeutic Goods Administration (TGA) has taken steps today to quarantine CSL Human Albumin solutions from further use while an assessment is undertaken of the safety of these products.
-
Safety alertsHuman albumin: Clinical advice on ethylene glycol
-
Market actionsAbout Octagam 5%: lifting of the voluntary recall
-
Market actionsThe Therapeutic Goods Administration (TGA) advises that Octapharma Australia Pty Ltd has agreed to a precautionary voluntary recall of all batches of Octagam intravenous immunoglobulin solutions from the Australian market.